|
2023-01-05 |
2023-01-03 |
PS
Planned sale
|
Mor George Adi
Chief Scientific Officer
Executive Director
|
6,100
-2.4%
5.03
USD 30,663
|
6,100
-2.4%
|
5.03
|
USD 30,663
|
|
|
2023-01-05 |
2023-01-03 |
PS
Planned sale
|
Mor George Adi
Chief Scientific Officer
Executive Director
|
7,700
-2.4%
5.03
USD 38,706
|
7,700
-2.4%
|
5.03
|
USD 38,706
|
|
|
2023-01-05 |
2023-01-03 |
S
Sale
|
OrbiMed Israel GP Ltd.
Large shareholder
|
70,524
-3.1%
4.51
USD 318,063
|
70,524
-3.1%
|
4.51
|
USD 318,063
|
|
|
2023-01-05 |
2023-01-03 |
S
Sale
|
OrbiMed Israel GP Ltd.
Large shareholder
|
266,376
-10.3%
3.34
USD 889,696
|
266,376
-10.3%
|
3.34
|
USD 889,696
|
|
|
2022-11-18 |
2022-11-16 |
S
Sale
|
Cohen Neil Harris
Non-Executive Director
|
2,409
-19.4%
2.00
USD 4,818
|
2,409
-19.4%
|
2.00
|
USD 4,818
|
|
|
2022-11-17 |
2022-11-16 |
S
Sale
|
Mor George Adi
Chief Scientific Officer
Executive Director
|
257,248
-50.0%
2.08
USD 536,311
|
257,248
-50.0%
|
2.08
|
USD 536,311
|
|
|
2022-11-17 |
2022-11-16 |
S
Sale
|
Mor George Adi
Chief Scientific Officer
Executive Director
|
324,775
-50.0%
2.08
USD 677,091
|
324,775
-50.0%
|
2.08
|
USD 677,091
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Maryles Joel Michael
Non-Executive Director
|
33
+2.4%
2.76
USD 91
|
33
+2.4%
|
2.76
|
USD 91
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Maryles Joel Michael
Non-Executive Director
|
400
+40.0%
2.89
USD 1,156
|
400
+40.0%
|
2.89
|
USD 1,156
|
|
|
2022-05-19 |
2022-05-18 |
B
Purchase
|
Cohen Neil Harris
Non-Executive Director
|
2,000
+19.2%
3.19
USD 6,380
|
2,000
+19.2%
|
3.19
|
USD 6,380
|
|
|
2022-03-21 |
2022-03-18 |
B
Purchase
|
Maryles Joel Michael
Non-Executive Director
|
500
+100.0%
4.36
USD 2,180
|
500
+100.0%
|
4.36
|
USD 2,180
|
|
|
2022-03-21 |
2022-03-18 |
B
Purchase
|
Maryles Joel Michael
Non-Executive Director
|
500
+inf%
4.32
USD 2,160
|
500
+inf%
|
4.32
|
USD 2,160
|
|
|
2022-06-21 |
2022-03-16 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+14.3%
3.25
USD 813
|
250
+14.3%
|
3.25
|
USD 813
|
|
|
2022-06-21 |
2022-03-16 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+16.7%
3.30
USD 825
|
250
+16.7%
|
3.30
|
USD 825
|
|
|
2022-03-21 |
2022-03-14 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+20.0%
4.20
USD 1,050
|
250
+20.0%
|
4.20
|
USD 1,050
|
|
|
2022-03-21 |
2022-03-14 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+25.0%
4.10
USD 1,025
|
250
+25.0%
|
4.10
|
USD 1,025
|
|
|
2022-03-21 |
2022-03-14 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+33.3%
3.90
USD 975
|
250
+33.3%
|
3.90
|
USD 975
|
|
|
2022-03-21 |
2022-03-14 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+100.0%
3.98
USD 995
|
250
+100.0%
|
3.98
|
USD 995
|
|
|
2022-03-21 |
2022-03-14 |
B
Purchase
|
Marvin Donald
Executive VP, CFO & COO
Officer
|
250
+inf%
4.00
USD 1,000
|
250
+inf%
|
4.00
|
USD 1,000
|
|
|
2022-03-15 |
2022-03-14 |
B
Purchase
|
Pfost Dale R
Chief Executive Officer
Executive Director
|
700
+38.9%
3.97
USD 2,779
|
700
+38.9%
|
3.97
|
USD 2,779
|
|
